A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three ...

For biopharma, reaching the right patients at the right time is essential for both clinical and commercial success. The right ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.